A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

This study is observing how well filgotinib (an oral medication) works in real-world clinical practice for Korean adults with moderate to severe ulcerative colitis — an inflammatory bowel condition that causes chronic colon inflammation. **You may be eligible if...** - You are between 19 and 64 years old - You have been diagnosed with moderately to severely active ulcerative colitis, confirmed by a bowel scope (endoscopy) - Your doctor has independently decided to prescribe filgotinib as part of your standard care **You may NOT be eligible if...** - You are under 19 or over 64 years old - You have Crohn's disease rather than ulcerative colitis - You have active serious infections or certain other health conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.